ASCO, ITT, KRAS-WT primary OS results: CALGB failed to meet its primary endpoint of OS Cetuximab is not superior to Avastin in 1L KRAS-WT. CALGB/SWOG Phase III trial of FOLFIRI or mFOLFOX6 with bevacizumab or cetuximab for patients with expanded RAS analyses in. CALGB/SWOG Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab.
|Published (Last):||21 December 2009|
|PDF File Size:||20.25 Mb|
|ePub File Size:||13.95 Mb|
|Price:||Free* [*Free Regsitration Required]|
Conflict of Interest Disclosures: Treatment assignments were generated according to randomly permuted blocks within strata. Response rates were not significantly different, Drafting of the manuscript: The data show that patients whose primary tumors originate on the left side of the colon the descending colon, sigmoid colon, and rectum survive significantly longer than those whose tumors originate on the right side the cecum and ascending colon.
The FIRE-3 investigators made an effort to document subsequent treatments and postulated that patients receiving first-line cetuximab treatment would have better overall survival because of a biological advantage when an EGFR inhibitor is followed by bevacizumab.
Patients in that treatment group were removed from the study, received treatment at the discretion of their physician, and were followed up per protocol. In Septemberthe combined treatment group of both cetuximab and bevacizumab with chemotherapeutic regimen was discontinued. Ethnicity was not considered other than descriptively. Eligible patients had pathology-documented untreated locally advanced or metastatic colorectal cancer, although measurable disease tumor that could be quantified caglb not require.
Therapeutic anticoagulation was permitted as long as the patient was therapeutic on a stable dose of anticoagulant. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
Meeting Library | Meeting Library
The primary outcome of progression-free survival was not statistically different between the panitumumab ccalgb bevacizumab treatment groups Eli Lilly provided the cetuximab. Sign in to make a comment Sign in to your personal account. Better chemotherapeutic regimens, patient selection, and changing multidisciplinary management likely contributed to these outcomes as did the exclusion of patients with KRAS mutations.
Results are reported for 1 the primary 2-group comparison between cetuximab and bevacizumab; 2 the comparison of cetuximab vs bevacizumab in an expanded RAS subset described above; and 3 the chemotherapy subgroups.
Sign in to access your subscriptions Sign in to your personal account. The primary statistical analyses were 2-sided tests of superiority comparing cetuximab vs bevacizumab with regard to the primary and main secondary outcomes among patients whose tumors were determined to be KRAS wt exon 2, codons 12,13 by Southwest Oncology Group review using intention-to-treat analyses.
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Create a free personal account to access your subscriptions, sign up for alerts, and more. Overall survival was Up to 6 months of prior adjuvant treatment had to have concluded at least 12 months before recurrence.
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. Second, this study only mandated first-line treatment with patients who at any time went more than 28 days without treatment being removed from study. Thus, these analyses should be considered exploratory.
Register for email alerts ccalgb links to free full-text articles Access PDFs of free articles Manage your interests Save searches and receive search alerts. The majority of patients also had access to both cetuximab and bevacizumab at progression because each biologic therapy was commercially available.
Create a free personal account to make a comment, download free article PDFs, sign up for alerts and more. Toxic effects that were lower than grade 3 were distinct with acneiform rash predominating for cetuximab and hypertension predominating for bevacizumab. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
Continuation of bevacizumab after first progression in metastatic colorectal cancer ML From September to Marchpatients were preregistered or registered, and patients were randomized to 1 of 3 treatment groups at study sites.
Back to top Article Information. Drs Venook and Niedzwiecki had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Initially, enrolled patients could consent to the biomarker companion study Cancer and Leukemia Group B and submit a specimen for EGFR status evaluation. This also contributed to the survival results.
For the primary analysis, researchers identified data from patients with right-sided primary tumors and patients with left-sided primary tumors.